Symphony Evolution

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Symphony Evolution sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 3 completed early-phase tilt top decile by trial count

Symphony Evolution: 10 sponsored US clinical trials, none currently recruiting.

Symphony Evolution sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Malignancies, with 1 trials.

Top-decile sponsor footprint

Symphony Evolution ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 0/100

3 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (30.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

COMPLETED Phase 1

Maintenance Study on the Long Term Safety of XL999

NCT00955084
TERMINATED Phase 1

Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer

NCT00491699
TERMINATED Phase 2

Study of XL999 in Patients With Acute Myeloid Leukemia (AML)

NCT00322673
COMPLETED Phase 2

Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy

NCT00312780
TERMINATED Phase 2

Study of XL999 in Patients With Multiple Myeloma

NCT00304590
TERMINATED Phase 2

Study of XL999 in Patients With Previously Treated Ovarian Cancer

NCT00277290
TERMINATED Phase 2

Study of XL999 in Patients With Metastatic Colorectal Cancer

NCT00277303
TERMINATED Phase 2

Study of XL999 in Patients With Non-small Cell Lung Cancer

NCT00277329
TERMINATED Phase 2

Study of XL999 in Patients With Metastatic Renal Cell Carcinoma

NCT00277316
COMPLETED Phase 1

Study of XL999 in Adults With Solid Tumors

NCT00104117

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 7

Therapeutic Areas

Advanced Malignancies 1

How the Symphony Evolution early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 3 completed (30%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Advanced Malignancies (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Symphony Evolution: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Symphony Evolution sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Symphony EvolutionAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron Pharmaceuticals10xBio22nd Century Group23andMe3-C Institute for Social Development
Symphony Evolution sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Symphony Evolution sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Symphony Evolution page

10 registered trials is a research-attention snapshot, not an endorsement of Symphony Evolution or any single study.

  • None of Symphony Evolution's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Advanced Malignancies is the condition Symphony Evolution studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Malignancies trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Symphony Evolution pipeline card: 10 registered trials from official public datasets.Report a data error.